Caribou Biosciences, Inc.

NASDAQ:CRBU

Biotechnology

Healthcare
$0.49 -2.74%

-$0.05 today

Market cap
$52.47M
Beta
2.33
P/E (TTM)
-1.1
EPS (TTM)
-$1.39
52W Low $1.20High $3.54

Volume 1.01M

Average 1.83M

CRBU Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Caribou Biosciences, Inc.NASDAQ: CRBU

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $25.09M (cash outflow) fell 37.3% year over year, behind the -9.9% change in trailing-twelve-month net income. Sequentially, it fell 5.3% from the prior quarter. Over 3 fiscal years it compounded at +14.2% a year.

Context

  • Net income amounted to 1327.4% of revenue in FY2025, down 164.5 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$83.3M (-43.8%) for the fiscal year ending Dec 2026, a slowdown from the -0.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$25.09M-5.3% QoQ
Last fiscal yearDec 2025
-$148.13M-0.7% YoY
LTMMar 2026
-$133.22M-9.9% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-37.3%-39.5%-2.2 pp
1 year-0.7%-43.8%-43.1 pp
3-year CAGR+14.2%+1.6%-12.6 pp
5-year CAGR+16.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(148.13M) USD
Year-over-year change
+0.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CRBU compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -9.9% is the 5th highest of 11, against a peer median of -15.9%.
  • Net income amounts to 1189.1% of revenue for CRBU, versus a peer median of 527.6%.
CRBU Competitors
Net Income for CRBU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€340.16M EUR+84.7%+84.4%7587.8%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$173.76M USD-31.1%-16.9%—
CRBUCaribou Biosciences, Inc.LTM Mar 2026$133.22M USD-9.9%+14.2%1189.1%
HUMAHumacyte, Inc.LTM Mar 2026$97.59M USD+25.7%+50.6%4840.8%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$83.01M USD-21.5%-9.9%36891.1%
PYXSPyxis Oncology, Inc.LTM Mar 2026$81.74M USD-14.2%-13.0%589.8%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$77.8M USD-39.1%-4.8%465.3%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$75.32M USD-6.4%-12.0%266.9%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$69.87M USD+152.1%+61.9%—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$61.98M USD-35.7%-12.4%89.6%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$54.64M USD-17.6%+16.2%167.0%
Peer median (excluding CRBU) —-15.9%-7.3%527.6%

Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(66.92M)(99.42M)(102.07M)(149.11M)(148.13M)
Depreciation & Amortization984K3.64M3.53M3.93M3.65M
Deferred Income Tax0(95K)00(548K)
Stock-Based Compensation3.45M11.72M13.75M16.71M12.68M
Change in Working Capital29.07M(4.11M)(7.32M)(5.11M)(484K)
Accounts Receivables(2.96M)3.46M805K608K272K
Inventory00000
Accounts Payables1.14M(2.72M)1.82M(354K)3.25M
Other Working Capital30.89M(4.85M)(9.94M)(5.37M)(4.01M)
Other Non-Cash Items904K9.02M(1.18M)(4.61M)21.84M
Operating Cash Flow(32.52M)(90.97M)(93.29M)(138.2M)(110.99M)
Capital Expenditures(3.12M)(6.45M)(11.61M)(6.51M)(1.36M)
Acquisitions (Net)00000
Purchases of Investments(173.28M)(339.06M)(394.76M)(304.39M)(150.37M)
Sales of Investments0252.87M338.19M397.49M252.83M
Other Investing Activities(1M)(600K)0(1.61M)1.14M
Investing Cash Flow(176.4M)(93.25M)(68.18M)86.61M102.24M
Debt Repayment1.03M0000
Common Stock Issued321.02M2.13M152.72M15.19M4.82M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.55M01.58M1.53M0
Financing Cash Flow433.43M2.13M154.3M16.72M4.82M
Effect of Forex Changes00000
Net Change in Cash224.51M(182.08M)(7.18M)(34.87M)(3.93M)
Free Cash Flow(35.64M)(97.42M)(104.9M)(144.71M)(112.35M)

Caribou Biosciences, Inc.

NASDAQ:CRBU

Intrinsic Alpha fair value

Locked

Current Price

$0.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.